Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI

Journal of Pediatric Rehabilitation Medicine

Volumn 3, Issue 2, 2010, Pages 129-138

  Alliston, Tamara ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chondroitin sulfate; growth plate; MPS VI; osteoblast and chondrocyte differentiation; TGF

Indexed keywords

[5 (2,4 DICHLOROBENZOYL) 2 HYDROXYPHENYL]ACETIC ACID; CHONDROITIN SULFATE; DERMATAN SULFATE; GALSULFASE; GLYCOSAMINOGLYCAN; GROWTH FACTOR; N ACETYLGALACTOSAMINE 4 SULFATASE;

BONE DEVELOPMENT; BONE DISEASE; BONE MARROW TRANSPLANTATION; CARTILAGE CELL; CELL DIFFERENTIATION; CELL FUNCTION; GENE TARGETING; GLYCOSAMINOGLYCAN METABOLISM; GROWTH PLATE; HUMAN; MAROTEAUX LAMY SYNDROME; MOLECULAR INTERACTION; OSTEOBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77954644714     PISSN: 18745393     EISSN: 18758894     Source Type: Journal    
DOI: 10.3233/PRM-2010-0117     Document Type: Review

References (74)

1. S. Abreu et al., Growth plate pathology in feline mucopolysaccharidosis VI, Calcif Tissue Int 57(3) (1995), 185-190.
2. T. Alliston, E. Piek and R. Derynck, TGF-beta family signaling in sketetal development, maintenance, and disease, in: The TGF-beta Family, R. Derynck and K. Miyazono, eds, Cold Spring Harbor Press: Woodbury, NY, 2008, pp. 667-723.
3. T. Alliston et al., TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation, EMBO J 20(9) (2001), 2254-2272.
4. J.P. Annes, J.S. Munger and D.B. Rifkin, Making sense of latent TGFbeta activation, J Cell Sci 116(Pt 2) (2003), 217-224.
5. G. Balooch et al., TGF-beta regulates the mechanical properties and composition of bone matrix, Proc Natl Acad Sci USA 102(52) (2005), 18813-18818.
6. J. Bielicki et al., Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI, J Biol Chem 274(51) (1999), 36335-36343.
7. A.J. Borton et al., The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis, J Bone Miner Res 16(10) (2001), 1754-1764.
8. S. Byers et al., Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS, Mol Genet Metab 65(4) (1998), 282-290.
9. E. Canalis, A.N. Economides and E. Gazzerro, Bone morphogenetic proteins, their antagonists, and the skeleton, Endocr Rev 24(2) (2003), 218-235.
10. A. Corsi et al., Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues, J Bone Miner Res 17(7) (2002), 1180-1189.
11. S.L. Dallas, T. Alliston and L.F. Bonewald, Transforming Growth Factor -beta, in: Principles of Bone Biology, J.P. Bilezikian, L.G. Raisz and G.A. Rodan, eds, Academic Press: San Diego, CA, 2008, pp. 1145-1166.
12. R. Derynck and K. Miyazono, TGF-beta and the TGF-beta Family, in: The TGF-beta Family, R. Derynck and K. Miyazono, eds, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY. 2008, pp. 29-44.
13. R. Derynck et al., TGF-beta family signaling in mesenchymal differentiation, in: The TGF-beta Family, R. Derynck and K. Miyazono, eds, Cold Spring Harbor Press: Woodbury, NY, 2008, pp. 613-655.
14. M. Evers et al., Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI, Proc Natl Acad Sci USA 93(16) (1996), 8214-8219.
15. X.H. Feng and R. Derynck, Specificity and versatility in TGFbeta signaling through Smads, Annu Rev Cell Dev Biol 21 (2005), 659-693.
16. X.H. Feng et al., The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation, Genes Dev 12(14) (1998), 2153-2163.
17. E. Filvaroff et al., Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass, Development 126(19) (1999), 4267-4279.
18. S.W. Fox and A.C. Lovibond, Current insights into the role of transforming growth factor-beta in bone resorption, Mol Cell Endocrinol 243(1-2) (2005), 19-26.
19. A.G. Geiser et al., Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene, Bone 23(2) (1998), 87-93.
20. V. Geoffroy et al., High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage, Mol Cell Biol 22(17) (2002), 6222-6233.
21. T.A. Guise and J.M. Chirgwin, Transforming growth factorbeta in osteolytic breast cancer bone metastases, Clin Orthop Relat Res 415(Suppl) (2003), S32-S38.
22. J.P. Habashi et al., Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome, Science 312(5770) (2006), 117-121.
23. M. Haskins et al., Animal models for mucopolysaccharidoses and their clinical relevance, Acta Paediatr Suppl 91(439) (2002), 88-97.
24. H. Hausser et al., Selective inactivity of TGF-beta/decorin complexes, FEBS Lett 353(3) (1994), 243-245.
25. E. Hay et al., Bone morphogenetic protein receptor IB signaling mediates apoptosis independently of differentiation in osteoblastic cells, J Biol Chem 279(3) (2004), 1650-1658.
26. C.J. Hernandez and T.M. Keaveny, A biomechanical perspective on bone quality, Bone 39(6) (2006), 1173-1181.
27. A. Hildebrand et al., Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta, Biochem J 302(Pt 2) (1994), 527-534.
28. M. Horiki et al., Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia, J Cell Biol 165(3) (2004), 433-445.
29. M. Ishii et al., Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis, Nature 458(7237) (2009), 524-528.
30. R. Janknecht, N.J. Wells and T. Hunter, TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300, Genes Dev 12(14) (1998), 2114-2119.
31. K. Janssens et al., Transforming growth factor-beta1 to the bone, Endocr Rev 26(6) (2005), 743-774.
32. V.M. Kahari, H. Larjava and J. Uitto, Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture, J Biol Chem 266(16) (1991), 10608-10615.
33. J.S. Kang et al., Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3, EMBO J 24(14) (2005), 2543-2555.
34. G. Karsenty and E.F. Wagner, Reaching a genetic and molecular understanding of skeletal development, Dev Cell 2(4) (2002), 389-406.
35. K.C. Kirkbride et al., Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor, J Biol Chem 283(12) (2008), 7628-7637.
36. C.B. Kirn-Safran et al., Heparan sulfate proteoglycans: coordinators of multiple signaling pathways during chondrogenesis, Birth Defects Res C Embryo Today 72(1) (2004), 69-88.
37. M. Kluppel et al., Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis, Development 132(17) (2005), 3989-4003.
38. M. Kusche-Gullberg and L. Kjellen, Sulfotransferases in glycosaminoglycan biosynthesis, Curr Opin Struct Biol 13(5) (2003), 605-611.
39. T.F. Li et al., Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation, J Bone Miner Res 21(1) (2006), 4-16.
40. X. Lin, Functions of heparan sulfate proteoglycans in cell signaling during development, Development 131(24) (2004), 6009-6021.
41. B.L. Loeys et al., A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2, Nat Genet 37(3) (2005), 275-281.
42. L.G. Lyons et al., Interleukin-1 beta and transforming growth factor- alpha/epidermal growth factor induce expression of M(r) 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes, J Biol Chem 268(25) (1993), 19143-19151.
43. S. Maeda et al., Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells, EMBO J 23(3) (2004), 552-563.
44. P.G. Maquet, A.J. Van de Berg and J.C. Simonet, Femorotibial weight-bearing areas. Experimental determination, J Bone Joint Surg Am 57(6) (1975), 766-771.
45. J.A. Metcalf et al., Mechanism of shortened bones in mucopolysaccharidosis VII, Mol Genet Metab 97(3) (2009), 202-211.
46. K.S. Mohammad et al., Pharmacologic inhibition of the TGFbeta type I receptor kinase has anabolic and anti-catabolic effects on bone, PLoS ONE 4(4) (2009), e5275.
47. E.R. Neptune et al., Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome, Nat Genet 33(3) (2003), 407-411.
48. E. Neufeld and J. Muenzer, The mucopolysaccharidoses, in: The metabolic and molecular bases of inherited disease, C. Scriver et al., eds, McGraw-Hill: New York, 2001, pp. 3421- 3452.
49. R.W. Norrdin et al., Bone changes in mucopolysaccharidosis VI in cats and the effects of bone marrow transplantation: mechanical testing of long bones, Bone 17(5) (1995), 485-489.
50. R.W. Norrdin et al., Characterization of osteopenia in feline mucopolysaccharidosis VI and evaluation of bone marrow transplantation therapy, Bone 14(3) (1993), 361-367.
51. J.D. Nuttall et al., Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI, Calcif Tissue Int 65(1) (1999), 47-52.
52. M. Okamoto et al., Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development, J Bone Miner Res 21(7) (2006), 1022-1033.
53. C.M. Overall, J.L. Wrana and J. Sodek, Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta, J Biol Chem 264(3) (1989), 1860-1869.
54. K.A. Radek, K.R. Taylor and R.L. Gallo, FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation, Wound Repair Regen 17(1) (2009), 118-126.
55. F. Ramirez and H.C. Dietz, Marfan syndrome: from molecular pathogenesis to clinical treatment, Curr Opin Genet Dev 17(3) (2007), 252-258.
56. L. Ravanti et al., Transforming growth factor-beta induces collagenase -3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase, J Biol Chem 274(52) (1999), 37292-37300.
57. K.N. Retting et al., BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation, Development 136(7) (2009), 1093-1104.
58. O. Sheridan et al., Craniofacial abnormalities in animal models of mucopolysaccharidoses I, VI, and VII, J Craniofac Genet Dev Biol 14(1) (1994), 7-15.
59. Y. Shi and J. Massague, Mechanisms of TGF-beta signaling from cell membrane to the nucleus, Cell 113(6) (2003), 685-700.
60. C.M. Simonaro et al., Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models, Pediatr Res 57(5 Pt 1) (2005), 701-707.
61. C.M. Simonaro et al., Mechanism of glycosaminoglycanmediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases, Am J Pathol 172(1) (2008), 112-122.
62. C.M. Simonaro, M.E. Haskins and E.H. Schuchman, Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses, Lab Invest 81(9) (2001), 1319-1328.
63. T. Suda et al., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families, Endocr Rev 20(3) (1999), 345-357. (Pubitemid 30649812)
64. Y. Takeuchi, Y. Kodama and T. Matsumoto, Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity, J Biol Chem 269(51) (1994), 32634-32638.
65. P. ten Dijke and C.S. Hill, New insights into TGF-beta-Smad signalling, Trends Biochem Sci 29(5) (2004), 265-273.
66. H. Thiele et al., Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement, Proc Natl Acad Sci USA 101(27) (2004), 10155-10160.
67. J.M. Trowbridge and R.L. Gallo, Dermatan sulfate: new functions from an old glycosaminoglycan, Glycobiology 12(9) (2002), 117R-125R.
68. S. Varghese et al., Chondroitin sulfate based niches for chondrogenic differentiation of mesenchymal stem cells, Matrix Biol 27(1) (2008), 12-21.
69. S. Wilson et al., Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities, Am J Pathol 175 (2009), 2053-2062.
70. T. Xu et al., Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice, Nat Genet 20(1) (1998), 78-82.
71. Y. Yamaguchi, D.M. Mann and E. Ruoslahti, Negative regulation of transforming growth factor-beta by the proteoglycan decorin, Nature 346(6281) (1990), 281-284.
72. J. Zhang et al., Smad4 is required for the normal organization of the cartilage growth plate, Dev Biol 284(2) (2005), 311-322.
73. Y. Zhang, X.H. Feng and R. Derynck, Smad3 and Smad4 cooperate with c- Jun/c-Fos to mediate TGF-beta-induced transcription, Nature 394(6696) (1998), 909-913.
74. Y.E. Zhang, Non-Smad pathways in TGF-beta signaling, Cell Res 19(1) (2009), 128-139